HomeNewsIndiaMC Interview | Made in India CoWIN ready to go global: RS Sharma

MC Interview | Made in India CoWIN ready to go global: RS Sharma

Every strategy is being applied to ensure people get their second dose, says CoWIN chief RS Sharma, as India touches a new record in daily vaccinations

August 30, 2021 / 10:25 IST
Story continues below Advertisement
India recorded a milestone daily COVID-19 vaccinations of over 1 crore jabs in a day on August 27 and CoWIN - the country's delivery tech platform is designed to absorb even higher numbers, RS Sharma, CEO of the National Health Authority told Moneycontrol. (Representative image)
India recorded a milestone daily COVID-19 vaccinations of over 1 crore jabs in a day on August 27 and CoWIN - the country's delivery tech platform is designed to absorb even higher numbers, RS Sharma, CEO of the National Health Authority told Moneycontrol. (Representative image)

Congratulatory messages poured in for India on August 27 after it recorded a fresh milestone in daily vaccinations against COVID-19 — over 1 crore or 10 million jabs in a day — a number that is a multiple of the population of many countries.

RS Sharma, CEO of the National Health Authority, said India’s COVID-19 vaccine delivery tech platform CoWin has been designed to absorb even higher numbers and can make swift changes in line with the Government’s vaccination policy.

Story continues below Advertisement

Sharma, who is chairperson of the empowered committee for CoWin, said every jab is recorded, even if people are not registered on CoWIN, and that concerted efforts are being made by various stakeholders to ensure people also get their second dose of the vaccine.

As the former chief of the Unique Identification Authority of India (UIDAI), the semi-government body tasked with rolling out the national identity project Aadhaar, Sharma believes the Made in India CoWin is now ready for the world.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show